Ascletis Draws GIC to First Pre-Profit Biotech IPO in Hong Kong

Bookmark
(Bloomberg) -- Ascletis Pharma Inc., the first biotech company to take advantage of new Hong Kong listing rules, is seeking to raise as much as $457 million in an initial public offering in the city.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.